mTABLET ABI

MESI mTABLET ABI: Leading the Way in Peripheral Arterial Disease Screening

Introducing the MESI mTABLET ABI, a game-changer in cardiovascular diagnostics, specially designed for Australian healthcare. This innovative device offers a solution previously unavailable and enables general practices across the country to quickly and accurately detect Peripheral Arterial Disease.

The Ankle-Brachial Index (ABI) is a vital indicator for detecting Peripheral Arterial Disease (PAD), a serious cardiovascular condition that can significantly impact your health and quality of life.

Why PAD Matters

PAD is associated with a high mortality rate, making early detection and management crucial for better health outcomes.

Early PAD .png

The ABI Challenge
Despite its importance, ABI measurements are not routinely performed in many healthcare settings. Why? The traditional method using Doppler ultrasound is:

Time-consuming
Complex to administer
Requires specialised training

The Smartest Wireless Ankle-Brachial Index
MESI mTABLET ABI for Australian Healthcare Professionals

The MESI mTABLET ABI offers Australian GP's and healthcare professionals a game-changing solution for quick and accurate Peripheral Arterial Disease (PAD) detection. This innovative device streamlines the measurement of Ankle-Brachial Index (ABI), a critical indicator of cardiovascular health.

The MESI mTABLET ABI is an innovative medical device designed to revolutionise Peripheral Arterial Disease (PAD) screening in Australian general practices and healthcare settings. This advanced diagnostic tool offers a quick and efficient method for measuring the Ankle-Brachial Index (ABI), a crucial indicator of PAD.

Key Features for Australian GPs:

Rapid ABI Measurement: Take advantage of the world's fastest ABI test for huge time savings in consultations without compromising on reading accuracy.
Wireless Convenience: Utilising innovative 3CUFF technology, the MESI mTABLET ABI allows for simultaneous brachial and ankle pressure measurement without the tangles of cables.
Seamless System Integration: It integrates in a complementary manner with existing EHR systems in various clinics across Australia. This avoids disruptions in workflows.
Versatile Applications: Ideal for primary care, vascular medicine, and chronic disease management in the Australian healthcare context.
Multiple Diagnostic Tools: Expandable platform including ECG, spirometry, and blood pressure measurements.

Designed for Comprehensive Cardiovascular Care

Varied applications: This include that the MESI mTABLET ABI is not intended for screening for PAD only but finds its ideal application in primary care, vascular medicine, and management of chronic diseases, hence finding its place in the versatile toolset within the Australian healthcare landscape.
Expandable Diagnostics: Expand your diagnostic circle with other modalities, including ECG, spirometry, and blood pressure on one platform.

Transforming Patient Care in Australia

Early detection of PAD holds significant implications for the management of cardiovascular risk, especially among the growing aged population in Australia.
Efficient Practice: This streamlines the diagnosis process, hence allowing more patients to be consulted within less time.
Improved Patient Outcomes: Early diagnosis and symptom-free detection result in better management of vascular health, thereby contributing to overall patient care.
Cost-effective: reduces referrals to specialist vascular services, which keeps costs lower for the patients and practices involved.

Join the Revolution in Cardiovascular Screening

The MESI mTABLET ABI represents a significant advancement in the point-of-care diagnostics available to Australian GPs and healthcare professionals. It empowers providers to deliver high-quality, evidence-based cardiovascular care with greater efficiency and accuracy.

Early detection of PAD holds significant implications for the management of cardiovascular risk, especially among the growing aged population in Australia.
Efficient Practice: This streamlines the diagnosis process, hence allowing more patients to be consulted within less time.
Improved Patient Outcomes: Early diagnosis and symptom-free detection result in better management of vascular health, thereby contributing to overall patient care.
Cost-effective: reduces referrals to specialist vascular services, which keeps costs lower for the patients and practices involved.

Equip your practice with the MESI mTABLET ABI system and elevate your diagnostic capabilities.
Ensure the best care for your patients with this state-of-the-art tool designed specifically for healthcare professionals in Australia.

CALL US TODAY!

For more information on how the MESI mTABLET can benefit your Australian general practice, please contact your Internal Sales Professional or our friendly Customer Service team on 1300 557 651.